JP2018525028A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018525028A5 JP2018525028A5 JP2018520386A JP2018520386A JP2018525028A5 JP 2018525028 A5 JP2018525028 A5 JP 2018525028A5 JP 2018520386 A JP2018520386 A JP 2018520386A JP 2018520386 A JP2018520386 A JP 2018520386A JP 2018525028 A5 JP2018525028 A5 JP 2018525028A5
- Authority
- JP
- Japan
- Prior art keywords
- bgag
- vlp
- target pathogen
- gene
- different target
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims description 87
- 102000004169 proteins and genes Human genes 0.000 claims description 43
- 244000052769 pathogen Species 0.000 claims description 34
- 230000001717 pathogenic effect Effects 0.000 claims description 32
- 241000700605 Viruses Species 0.000 claims description 17
- 239000013598 vector Substances 0.000 claims description 14
- 229960005486 vaccine Drugs 0.000 claims description 13
- 239000013612 plasmid Substances 0.000 claims description 12
- 238000012546 transfer Methods 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 8
- 101710182846 Polyhedrin Proteins 0.000 claims description 7
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 241000712461 unidentified influenza virus Species 0.000 claims description 6
- 230000028993 immune response Effects 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 238000002255 vaccination Methods 0.000 claims description 3
- 241000271566 Aves Species 0.000 claims description 2
- 241000711573 Coronaviridae Species 0.000 claims description 2
- 241000711950 Filoviridae Species 0.000 claims description 2
- 108010067390 Viral Proteins Proteins 0.000 claims description 2
- 239000002671 adjuvant Substances 0.000 claims description 2
- 238000010367 cloning Methods 0.000 claims description 2
- 201000010099 disease Diseases 0.000 claims description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 239000012528 membrane Substances 0.000 claims description 2
- 241001430294 unidentified retrovirus Species 0.000 claims description 2
- 230000002596 correlated effect Effects 0.000 claims 1
- 238000001814 protein method Methods 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 12
- 101150080862 NA gene Proteins 0.000 description 11
- 206010022000 influenza Diseases 0.000 description 9
- 101710132601 Capsid protein Proteins 0.000 description 7
- 101150039660 HA gene Proteins 0.000 description 6
- 101150109178 M1 gene Proteins 0.000 description 5
- 108020004705 Codon Proteins 0.000 description 4
- 241000238631 Hexapoda Species 0.000 description 3
- 241000701447 unidentified baculovirus Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 241000713704 Bovine immunodeficiency virus Species 0.000 description 1
- 101710177291 Gag polyprotein Proteins 0.000 description 1
- 101150072436 H1 gene Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713666 Lentivirus Species 0.000 description 1
- 101710125418 Major capsid protein Proteins 0.000 description 1
- 241000712907 Retroviridae Species 0.000 description 1
- 241000256251 Spodoptera frugiperda Species 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 108700004026 gag Genes Proteins 0.000 description 1
- 101150098622 gag gene Proteins 0.000 description 1
- 230000007236 host immunity Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 229940125575 vaccine candidate Drugs 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562188084P | 2015-07-02 | 2015-07-02 | |
| US62/188,084 | 2015-07-02 | ||
| PCT/US2016/040838 WO2017004586A1 (en) | 2015-07-02 | 2016-07-01 | Recombinant virus like particles using bovine immunodeficiency virus gag protein |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020153664A Division JP2020198893A (ja) | 2015-07-02 | 2020-09-14 | ウシ免疫不全ウイルスｇａｇタンパク質を使用する組換えウイルス様粒子 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018525028A JP2018525028A (ja) | 2018-09-06 |
| JP2018525028A5 true JP2018525028A5 (enExample) | 2019-08-08 |
| JP6978079B2 JP6978079B2 (ja) | 2021-12-08 |
Family
ID=57609369
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018520386A Active JP6978079B2 (ja) | 2015-07-02 | 2016-07-01 | ウシ免疫不全ウイルスｇａｇタンパク質を使用する組換えウイルス様粒子 |
| JP2020153664A Withdrawn JP2020198893A (ja) | 2015-07-02 | 2020-09-14 | ウシ免疫不全ウイルスｇａｇタンパク質を使用する組換えウイルス様粒子 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020153664A Withdrawn JP2020198893A (ja) | 2015-07-02 | 2020-09-14 | ウシ免疫不全ウイルスｇａｇタンパク質を使用する組換えウイルス様粒子 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US11576965B2 (enExample) |
| EP (1) | EP3316906A4 (enExample) |
| JP (2) | JP6978079B2 (enExample) |
| KR (1) | KR20180032586A (enExample) |
| CN (2) | CN108348596B (enExample) |
| BR (1) | BR112018000037A2 (enExample) |
| CA (1) | CA2991213A1 (enExample) |
| EA (1) | EA201890187A1 (enExample) |
| MA (1) | MA42312A (enExample) |
| MX (1) | MX390927B (enExample) |
| PE (1) | PE20180771A1 (enExample) |
| RU (2) | RU2757723C2 (enExample) |
| WO (1) | WO2017004586A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA42312A (fr) * | 2015-07-02 | 2018-05-09 | Medigen Inc | Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine |
| CN112279900A (zh) * | 2020-12-30 | 2021-01-29 | 乾元浩生物股份有限公司 | H9n2亚型禽流感病毒基因工程亚单位疫苗及其制备方法与应用 |
| CN113403343A (zh) * | 2021-04-30 | 2021-09-17 | 吉林大学 | 一种h3n2与h9n2亚型禽流感二价嵌合型病毒样颗粒的制备 |
| CN113398259A (zh) * | 2021-04-30 | 2021-09-17 | 吉林大学 | 一种h9n2亚型禽流感新型标记疫苗的制备方法及其应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6864085B2 (en) | 1999-12-14 | 2005-03-08 | Novartis Ag | Bovine immunodeficiency virus (BIV) based vectors |
| EP1576143B1 (en) | 2002-05-17 | 2010-11-24 | Emory University | Virus-like particles, methods of preparation, and immonogenic compositions |
| WO2004042001A2 (en) * | 2002-05-17 | 2004-05-21 | Emory University | Virus-like particles, methods of preparation, and immonogenic compositions |
| US8506967B2 (en) * | 2003-07-11 | 2013-08-13 | Novavax, Inc. | Functional influenza virus like particles (VLPs) |
| WO2008005777A2 (en) | 2006-06-30 | 2008-01-10 | Novavax, Inc. | Methods of enhancing protein incorporation into virus like particles |
| WO2008094200A2 (en) | 2006-07-27 | 2008-08-07 | Ligocyte Pharmaceuticals, Inc | Chimeric virus-like particles |
| US20100247574A1 (en) | 2007-02-21 | 2010-09-30 | Kutub Mahmood | CHIMERIC NEWCASTLE DISEASE VIRUS VLPs |
| SG10201903161XA (en) | 2007-05-29 | 2019-05-30 | Christopher Reid | Methods for production and uses of multipotent cell populations |
| AU2008275895A1 (en) * | 2007-07-19 | 2009-01-22 | Novavax, Inc. | Varicella Zoster Virus-virus like particles (VLPS) and antigens |
| WO2011087839A1 (en) * | 2009-12-22 | 2011-07-21 | Baxter International Inc. | Vaccine to influenza a virus |
| US20110293700A1 (en) * | 2010-05-26 | 2011-12-01 | Selecta Biosciences, Inc. | Nanocarrier compositions with uncoupled adjuvant |
| US20140004146A1 (en) * | 2011-03-17 | 2014-01-02 | Institut Pasteur Of Shanghai, Chinese Academy Of Sciences | Method for producing virus-like particle by using drosophila cell and applications thereof |
| WO2015066715A1 (en) | 2013-11-04 | 2015-05-07 | Viracell Advanced Products, Llc | Virus-like particles and methods related thereto |
| MA42312A (fr) * | 2015-07-02 | 2018-05-09 | Medigen Inc | Particules de type virus recombinantes utilisant la protéine gag du virus de l'immunodéficience bovine |
-
2016
- 2016-07-01 MA MA042312A patent/MA42312A/fr unknown
- 2016-07-01 JP JP2018520386A patent/JP6978079B2/ja active Active
- 2016-07-01 RU RU2020125098A patent/RU2757723C2/ru active
- 2016-07-01 KR KR1020187003292A patent/KR20180032586A/ko not_active Ceased
- 2016-07-01 CN CN201680050161.9A patent/CN108348596B/zh active Active
- 2016-07-01 EP EP16818931.4A patent/EP3316906A4/en active Pending
- 2016-07-01 WO PCT/US2016/040838 patent/WO2017004586A1/en not_active Ceased
- 2016-07-01 MX MX2018000023A patent/MX390927B/es unknown
- 2016-07-01 PE PE2018000003A patent/PE20180771A1/es not_active Application Discontinuation
- 2016-07-01 BR BR112018000037A patent/BR112018000037A2/pt active Search and Examination
- 2016-07-01 RU RU2018103757A patent/RU2734118C2/ru active
- 2016-07-01 CN CN202210931466.8A patent/CN115927212A/zh active Pending
- 2016-07-01 US US15/741,443 patent/US11576965B2/en active Active
- 2016-07-01 CA CA2991213A patent/CA2991213A1/en active Pending
- 2016-07-01 EA EA201890187A patent/EA201890187A1/ru unknown
-
2020
- 2020-09-14 JP JP2020153664A patent/JP2020198893A/ja not_active Withdrawn
-
2023
- 2023-01-12 US US18/153,667 patent/US12303560B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| López-Macías et al. | Safety and immunogenicity of a virus-like particle pandemic influenza A (H1N1) 2009 vaccine in a blinded, randomized, placebo-controlled trial of adults in Mexico | |
| Stech et al. | A new approach to an influenza live vaccine: modification of the cleavage site of hemagglutinin | |
| Liu et al. | Recombinant virus-like particles elicit protective immunity against avian influenza A (H7N9) virus infection in ferrets | |
| Bardiya et al. | Influenza vaccines: recent advances in production technologies | |
| US8597661B2 (en) | Neuraminidase-deficient live influenza vaccines | |
| Baz et al. | Nonreplicating influenza A virus vaccines confer broad protection against lethal challenge | |
| Tretyakova et al. | Intranasal vaccination with H5, H7 and H9 hemagglutinins co-localized in a virus-like particle protects ferrets from multiple avian influenza viruses | |
| US9017694B2 (en) | Swine influenza hemagglutinin variants | |
| Pushko et al. | Recombinant H1N1 virus-like particle vaccine elicits protective immunity in ferrets against the 2009 pandemic H1N1 influenza virus | |
| US9504741B2 (en) | Immune methods against influenza viruses and combinatorial vaccines thereof | |
| Cinatl Jr et al. | The threat of avian influenza A (H5N1). Part IV: development of vaccines | |
| EP3715458B1 (en) | H7 avian influenza vaccine strain which differentiates infected from vaccinated animals, preparation method therefor, and application | |
| KR102180774B1 (ko) | H5N8형 재조합 인플루엔자 A 바이러스 및 이를 포함하는 clade 2.3.4.4A에 속하는 H5 혈청형 인플루엔자 A 바이러스에 대한 백신 조성물 | |
| Masic et al. | Reverse genetics-generated elastase-dependent swine influenza viruses are attenuated in pigs | |
| JP2018525028A5 (enExample) | ||
| Chen et al. | The receptor binding specificity of the live attenuated influenza H2 and H6 vaccine viruses contributes to vaccine immunogenicity and protection in ferrets | |
| Duan et al. | Response of mice and ferrets to a monovalent influenza A (H7N9) split vaccine | |
| JP2020198893A (ja) | ウシ免疫不全ウイルスｇａｇタンパク質を使用する組換えウイルス様粒子 | |
| Tripp et al. | Animal models for evaluation of influenza vaccines | |
| Wang et al. | Protective efficacy of a broadly cross-reactive swine influenza DNA vaccine encoding M2e, cytotoxic T lymphocyte epitope and consensus H3 hemagglutinin | |
| Yi et al. | Molecular characterization of a virulent genotype VIId strain of Newcastle disease virus from farmed chickens in Shanghai | |
| CN103316357B (zh) | 携带rsv基因的重组流感病毒嵌合疫苗及其制备方法 | |
| Yang et al. | Immunogenicity and protective efficacy of a live attenuated vaccine against the 2009 pandemic A H1N1 in mice and ferrets | |
| Su et al. | Emergence and pandemic potential of avian influenza a (H7N9) virus | |
| KR102182987B1 (ko) | 재조합 인플루엔자 a 바이러스 h5n1주 및 이를 포함하는 고병원성 인플루엔자 a 바이러스 백신 조성물 |